

Sodium oxybate did not impair fertility in rats at doses up to 1000 mg/kg (approximately equal to the maximum recommended human daily dose on a mg/m^2 basis).

Pregnancy

Pregnancy Category B: Reproduction studies conducted in pregnant rats at doses up to 1000 mg/kg (approximately equal to the maximum recommended human daily dose on a mg/m^2 basis) and in pregnant rabbits at doses up to 1200 mg/kg (approximately 3 times the maximum recommended human daily dose on a mg/m^2 basis) revealed no evidence of teratogenicity. In a study in which rats were given sodium oxybate from day 6 of gestation through day 21 post-partum, slight decreases in pup and maternal weight gains were seen at 1000 mg/kg; there were no drug effects on other developmental parameters. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Labor and Delivery

Sodium oxybate has not been studied in labor or delivery. In obstetric anesthesia using an injectable formulation of sodium oxybate newborns had stable cardiovascular and respiratory measures but were very sleepy, causing a slight decrease in Apgar scores. There was a fall in the rate of uterine contractions 20 minutes after injection. Placental transfer is rapid, but umbilical vein levels of sodium oxybate were no more than 25% of the maternal concentration. No sodium oxybate was detected in the infant's blood 30 minutes after delivery. Elimination curves of sodium oxybate between a 2-day old infant and a 15-year old patient were similar. Subsequent effects of sodium oxybate on later growth, development and maturation in humans are unknown.

Nursing Mothers

It is not known whether sodium oxybate is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when sodium oxybate is administered to a nursing woman.

Pediatric Use

Safety and effectiveness in patients under 16 years of age have not been established.

Race and Gender Effects

effects on safety or efficacy. More than 90% of the subjects in clinical trials were Caucasian.

The database was 58% female.

The overall percentage of patients with at least one adverse event was slightly higher in women (80%) than in men (69%). The incidence of serious adverse events and discontinuations due to adverse events were similar in both men and women.

ADVERSE REACTIONS

A total of 448 narcoleptic patients were exposed to sodium oxybate in clinical trials. The most commonly observed adverse events associated with the use of sodium oxybate were:

Headache (25%), nausea (21%), dizziness (17%), pain (16%), somnolence (13%), pharyngitis (11%), infection (10%), viral infection (10%), flu syndrome (9%), accidental injury (9%), diarrhea (8%), urinary incontinence (8%), vomiting (8%), rhinitis (8%), asthenia (8%), sinusitis (7%), nervousness (7%), back pain (7%), confusion (7%), sleepwalking (7%), depression (6%), dyspepsia (6%), abdominal pain (6%), abnormal dreams (6%), insomnia (5%).

2 deaths occurred — these clinical trials, both from drug overdoses. Both these deaths resulted from the ingestion of multiple drugs, including sodium oxybate in one patient

In these clinical trials, 13% of patients discontinued because of adverse events. The most frequent reasons for discontinuation (> 1%) were nausea (2%) and headache (1.3%)

Approximately 6 % of patients receiving sodium oxybate in 3 controlled clinical trials (n=147) withdrew due to an adverse event, compared to 1% receiving placebo (n=79).

Incidence in Controlled Clinical Trials

Most Commonly Reported Adverse Events in Controlled Clinical Trials

The most commonly reported adverse events associated with the use of sodium oxybate and occurring with at least 5% greater frequency than seen in placebo-treated patients were dizziness (23%), headache (20%), nausea (16%), pain (12%), sleep disorder (9%), confusion (7%), infection (7%), vomiting (6%) and urinary incontinence (5%). These incidences are based on combined data from Trial 1 and two smaller randomized, double-blind, placebo-controlled, cross-over trials (n=181).

Trial 1, _____ used 3 fixed doses of sodium oxybate (3g, 6g, and 9g). In that trial dizziness, nausea, urinary incontinence, and vomiting were more common at higher doses, with the majority of events occurring in the 6g and 9g dose groups.

Adverse Events With an Incidence of > 1% in Trial 1

Table _____ lists the incidence of treatment emergent adverse events in Trial 1. Events have been included for which there are at least 2 episodes in the considered drug group and for which the incidence in at least one dosage group is greater on drug than placebo.

The prescriber should be aware that data provided below cannot be used to predict the incidence of adverse experiences during the course of usual medical practice where patient characteristics and other factors may differ from those occurring during clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. However, the cited figures do provide the prescribing physician with some basis for

estimating the relative contribution of drug and non-drug factors to the adverse event incidence rate in the population studied.

Table

**Incidence (%) of Treatment-Emergent Adverse Events in
Trial 1**

Body System Preferred Term	Sodium Oxybate Dose			
	Placebo (n=34)	3g (n=34)	6g (n=33)	9g (n=35)
<i>Body as a Whole</i>				
Asthenia	1 (3%)	0 (0%)	2 (6%)	0 (0%)
Flu Syndrome	0 (0%)	1 (3%)	0 (0%)	2 (6%)
Headache	7 (21%)	3 (9%)	5 (15%)	11 (31%)
Infection	1 (3%)	3 (9%)	5 (15%)	0 (0%)
Infection Viral	1 (3%)	1 (3%)	3 (9%)	0 (0%)
Pain	2 (6%)	3 (9%)	4 (12%)	7 (20%)
<i>Digestive System</i>				
Diarrhea	0 (0%)	0 (0%)	2 (6%)	2 (6%)
Dyspepsia	2 (6%)	0 (0%)	3 (9%)	2 (6%)
Nausea	2 (6%)	2 (6%)	5 (15%)	12 (34%)
Nausea and Vomiting	0 (0%)	0 (0%)	2 (6%)	2 (6%)
Vomiting	0 (0%)	0 (0%)	2 (6%)	4 (11%)
<i>Musculoskeletal System</i>				
Myasthenia	0 (0%)	2 (6%)	1 (3%)	0 (0%)
<i>Nervous System</i>				
Amnesia	0 (0%)	1 (3%)	0 (0%)	2 (6%)
Anxiety	1 (3%)	1 (3%)	0 (0%)	2 (6%)
Confusion	1 (3%)	3 (9%)	1 (3%)	5 (14%)
Dizziness	2 (6%)	8 (24%)	10 (30%)	12 (34%)
Dream Abnormal	0 (0%)	0 (0%)	3 (9%)	1 (3%)
Hypertension	1 (3%)	0 (0%)	2 (6%)	0 (0%)
Hypesthesia	0 (0%)	2 (6%)	0 (0%)	0 (0%)
Sleep Disorder	1 (3%)	2 (6%)	4 (12%)	5 (14%)

Skin

Special Senses

Urogenital System

Other Adverse Events Observed During All Clinical Trials

Body As A Whole

Cardiovascular system

Digestive system

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.